 | • レポートコード：MRC23Q35879 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のクロストリジウムディフィシルイムノアッセイ市場について調査・分析し、世界のクロストリジウムディフィシルイムノアッセイ市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（共通抗原（共通酵素/GDH）試験、Toxigenic Anaerobic Culture Test、Tissue Cytotoxin Neutralization Assay、Toxins A and B (EIA)）、用途別セグメント分析（病院、診療所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Hologic Inc.、TECHLAB, Inc.、Roche AG、Merck & Co.、Pfizer, Inc.、Actelion Pharmaceuticals、Thermo Fisher Scientific Inc.、Alere, Inc.、Trinity Biotech、Baxter International Inc.、Sanofi SA、Summit Therapeutics、AstraZeneca Plc.、Novartis AGなどが含まれています。 世界のクロストリジウムディフィシルイムノアッセイ市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、クロストリジウムディフィシルイムノアッセイ市場規模を推定する際に考慮しました。本レポートは、クロストリジウムディフィシルイムノアッセイの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、クロストリジウムディフィシルイムノアッセイに関するビジネス上の意思決定に役立てることを目的としています。 ・クロストリジウムディフィシルイムノアッセイ市場の概要 - クロストリジウムディフィシルイムノアッセイのタイプ別セグメント - 世界のクロストリジウムディフィシルイムノアッセイ市場規模：タイプ別分析（共通抗原（共通酵素/GDH）試験、Toxigenic Anaerobic Culture Test、Tissue Cytotoxin Neutralization Assay、Toxins A and B (EIA)） - クロストリジウムディフィシルイムノアッセイの用途別セグメント - 世界のクロストリジウムディフィシルイムノアッセイ市場規模：用途別分析（病院、診療所、その他） - 世界のクロストリジウムディフィシルイムノアッセイ市場規模予測（2018年-2029年） ・クロストリジウムディフィシルイムノアッセイ市場の成長トレンド - クロストリジウムディフィシルイムノアッセイの地域別市場規模（2018年-2029年） - クロストリジウムディフィシルイムノアッセイ市場ダイナミクス - クロストリジウムディフィシルイムノアッセイの業界動向 - クロストリジウムディフィシルイムノアッセイ市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：共通抗原（共通酵素/GDH）試験、Toxigenic Anaerobic Culture Test、Tissue Cytotoxin Neutralization Assay、Toxins A and B (EIA) - 世界のクロストリジウムディフィシルイムノアッセイのタイプ別市場規模（2018年-2023年） - 世界のクロストリジウムディフィシルイムノアッセイのタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、診療所、その他 - 世界のクロストリジウムディフィシルイムノアッセイの用途別市場規模（2018年-2023年） - 世界のクロストリジウムディフィシルイムノアッセイの用途別市場規模（2024年-2029年） ・クロストリジウムディフィシルイムノアッセイの地域別市場規模 - 北米のクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - アメリカのクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - ヨーロッパのクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - アジア太平洋のクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - 中国のクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - 日本のクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - 韓国のクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - インドのクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - オーストラリアのクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - 中南米のクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） - 中東・アフリカのクロストリジウムディフィシルイムノアッセイ市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Hologic Inc.、TECHLAB, Inc.、Roche AG、Merck & Co.、Pfizer, Inc.、Actelion Pharmaceuticals、Thermo Fisher Scientific Inc.、Alere, Inc.、Trinity Biotech、Baxter International Inc.、Sanofi SA、Summit Therapeutics、AstraZeneca Plc.、Novartis AG ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Clostridium Difficile Immunoassays market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Clostridium Difficile Immunoassays is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Clostridium Difficile Immunoassays is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Clostridium Difficile Immunoassays in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Clostridium Difficile Immunoassays include Hologic Inc., TECHLAB, Inc., Roche AG, Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Thermo Fisher Scientific Inc., Alere, Inc. and Trinity Biotech, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Clostridium Difficile Immunoassays, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clostridium Difficile Immunoassays.
The Clostridium Difficile Immunoassays market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Clostridium Difficile Immunoassays market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Clostridium Difficile Immunoassays companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Hologic Inc.
TECHLAB, Inc.
Roche AG
Merck & Co.
Pfizer, Inc.
Actelion Pharmaceuticals
Thermo Fisher Scientific Inc.
Alere, Inc.
Trinity Biotech
Baxter International Inc.
Sanofi SA
Summit Therapeutics
AstraZeneca Plc.
Novartis AG
Segment by Type
Common antigen (common enzyme or GDH) Test
Toxigenic Anaerobic Culture Test
Tissue Cytotoxin Neutralization Assay
Toxins A and B (EIA)
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Clostridium Difficile Immunoassays companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Clostridium Difficile Immunoassays Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Common antigen (common enzyme or GDH) Test
1.2.3 Toxigenic Anaerobic Culture Test
1.2.4 Tissue Cytotoxin Neutralization Assay
1.2.5 Toxins A and B (EIA)
1.3 Market by Application
1.3.1 Global Clostridium Difficile Immunoassays Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Clostridium Difficile Immunoassays Market Perspective (2018-2029)
2.2 Clostridium Difficile Immunoassays Growth Trends by Region
2.2.1 Global Clostridium Difficile Immunoassays Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Clostridium Difficile Immunoassays Historic Market Size by Region (2018-2023)
2.2.3 Clostridium Difficile Immunoassays Forecasted Market Size by Region (2024-2029)
2.3 Clostridium Difficile Immunoassays Market Dynamics
2.3.1 Clostridium Difficile Immunoassays Industry Trends
2.3.2 Clostridium Difficile Immunoassays Market Drivers
2.3.3 Clostridium Difficile Immunoassays Market Challenges
2.3.4 Clostridium Difficile Immunoassays Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Clostridium Difficile Immunoassays Players by Revenue
3.1.1 Global Top Clostridium Difficile Immunoassays Players by Revenue (2018-2023)
3.1.2 Global Clostridium Difficile Immunoassays Revenue Market Share by Players (2018-2023)
3.2 Global Clostridium Difficile Immunoassays Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Clostridium Difficile Immunoassays Revenue
3.4 Global Clostridium Difficile Immunoassays Market Concentration Ratio
3.4.1 Global Clostridium Difficile Immunoassays Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Clostridium Difficile Immunoassays Revenue in 2022
3.5 Clostridium Difficile Immunoassays Key Players Head office and Area Served
3.6 Key Players Clostridium Difficile Immunoassays Product Solution and Service
3.7 Date of Enter into Clostridium Difficile Immunoassays Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Clostridium Difficile Immunoassays Breakdown Data by Type
4.1 Global Clostridium Difficile Immunoassays Historic Market Size by Type (2018-2023)
4.2 Global Clostridium Difficile Immunoassays Forecasted Market Size by Type (2024-2029)
5 Clostridium Difficile Immunoassays Breakdown Data by Application
5.1 Global Clostridium Difficile Immunoassays Historic Market Size by Application (2018-2023)
5.2 Global Clostridium Difficile Immunoassays Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Clostridium Difficile Immunoassays Market Size (2018-2029)
6.2 North America Clostridium Difficile Immunoassays Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Clostridium Difficile Immunoassays Market Size by Country (2018-2023)
6.4 North America Clostridium Difficile Immunoassays Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Clostridium Difficile Immunoassays Market Size (2018-2029)
7.2 Europe Clostridium Difficile Immunoassays Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Clostridium Difficile Immunoassays Market Size by Country (2018-2023)
7.4 Europe Clostridium Difficile Immunoassays Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Clostridium Difficile Immunoassays Market Size (2018-2029)
8.2 Asia-Pacific Clostridium Difficile Immunoassays Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Clostridium Difficile Immunoassays Market Size by Region (2018-2023)
8.4 Asia-Pacific Clostridium Difficile Immunoassays Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Clostridium Difficile Immunoassays Market Size (2018-2029)
9.2 Latin America Clostridium Difficile Immunoassays Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Clostridium Difficile Immunoassays Market Size by Country (2018-2023)
9.4 Latin America Clostridium Difficile Immunoassays Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Clostridium Difficile Immunoassays Market Size (2018-2029)
10.2 Middle East & Africa Clostridium Difficile Immunoassays Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Clostridium Difficile Immunoassays Market Size by Country (2018-2023)
10.4 Middle East & Africa Clostridium Difficile Immunoassays Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Hologic Inc.
11.1.1 Hologic Inc. Company Detail
11.1.2 Hologic Inc. Business Overview
11.1.3 Hologic Inc. Clostridium Difficile Immunoassays Introduction
11.1.4 Hologic Inc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.1.5 Hologic Inc. Recent Development
11.2 TECHLAB, Inc.
11.2.1 TECHLAB, Inc. Company Detail
11.2.2 TECHLAB, Inc. Business Overview
11.2.3 TECHLAB, Inc. Clostridium Difficile Immunoassays Introduction
11.2.4 TECHLAB, Inc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.2.5 TECHLAB, Inc. Recent Development
11.3 Roche AG
11.3.1 Roche AG Company Detail
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Clostridium Difficile Immunoassays Introduction
11.3.4 Roche AG Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.3.5 Roche AG Recent Development
11.4 Merck & Co.
11.4.1 Merck & Co. Company Detail
11.4.2 Merck & Co. Business Overview
11.4.3 Merck & Co. Clostridium Difficile Immunoassays Introduction
11.4.4 Merck & Co. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.4.5 Merck & Co. Recent Development
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Company Detail
11.5.2 Pfizer, Inc. Business Overview
11.5.3 Pfizer, Inc. Clostridium Difficile Immunoassays Introduction
11.5.4 Pfizer, Inc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.5.5 Pfizer, Inc. Recent Development
11.6 Actelion Pharmaceuticals
11.6.1 Actelion Pharmaceuticals Company Detail
11.6.2 Actelion Pharmaceuticals Business Overview
11.6.3 Actelion Pharmaceuticals Clostridium Difficile Immunoassays Introduction
11.6.4 Actelion Pharmaceuticals Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.6.5 Actelion Pharmaceuticals Recent Development
11.7 Thermo Fisher Scientific Inc.
11.7.1 Thermo Fisher Scientific Inc. Company Detail
11.7.2 Thermo Fisher Scientific Inc. Business Overview
11.7.3 Thermo Fisher Scientific Inc. Clostridium Difficile Immunoassays Introduction
11.7.4 Thermo Fisher Scientific Inc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.7.5 Thermo Fisher Scientific Inc. Recent Development
11.8 Alere, Inc.
11.8.1 Alere, Inc. Company Detail
11.8.2 Alere, Inc. Business Overview
11.8.3 Alere, Inc. Clostridium Difficile Immunoassays Introduction
11.8.4 Alere, Inc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.8.5 Alere, Inc. Recent Development
11.9 Trinity Biotech
11.9.1 Trinity Biotech Company Detail
11.9.2 Trinity Biotech Business Overview
11.9.3 Trinity Biotech Clostridium Difficile Immunoassays Introduction
11.9.4 Trinity Biotech Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.9.5 Trinity Biotech Recent Development
11.10 Baxter International Inc.
11.10.1 Baxter International Inc. Company Detail
11.10.2 Baxter International Inc. Business Overview
11.10.3 Baxter International Inc. Clostridium Difficile Immunoassays Introduction
11.10.4 Baxter International Inc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.10.5 Baxter International Inc. Recent Development
11.11 Sanofi SA
11.11.1 Sanofi SA Company Detail
11.11.2 Sanofi SA Business Overview
11.11.3 Sanofi SA Clostridium Difficile Immunoassays Introduction
11.11.4 Sanofi SA Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.11.5 Sanofi SA Recent Development
11.12 Summit Therapeutics
11.12.1 Summit Therapeutics Company Detail
11.12.2 Summit Therapeutics Business Overview
11.12.3 Summit Therapeutics Clostridium Difficile Immunoassays Introduction
11.12.4 Summit Therapeutics Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.12.5 Summit Therapeutics Recent Development
11.13 AstraZeneca Plc.
11.13.1 AstraZeneca Plc. Company Detail
11.13.2 AstraZeneca Plc. Business Overview
11.13.3 AstraZeneca Plc. Clostridium Difficile Immunoassays Introduction
11.13.4 AstraZeneca Plc. Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.13.5 AstraZeneca Plc. Recent Development
11.14 Novartis AG
11.14.1 Novartis AG Company Detail
11.14.2 Novartis AG Business Overview
11.14.3 Novartis AG Clostridium Difficile Immunoassays Introduction
11.14.4 Novartis AG Revenue in Clostridium Difficile Immunoassays Business (2018-2023)
11.14.5 Novartis AG Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details